Get The Daily Rip

Stocktwits Top 25 – Week 47 πŸ“ˆ

Welcome to the Stocktwits Top 25 Newsletter for Week 47 of 2023!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.Β 

Here are the Stocktwits Top 25 Lists for Week 47:

P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Standard and Poor's 500

ST Top 25 S&P 500

The S&P 500 Top 25 list (+1.27%) outperformed the S&P 500 index (+1.00%).

There was one major changeΒ to the list this week.

Microsoft (+2.05%) replaced Expedia Group (+0.03%) on the list.

Check out how the momentum meter has performed vs. the S&P 500 index this year:


The Large-Cap Nasdaq 100

The Nasdaq 100 Top 25 list (+1.56%) outperformed the Nasdaq 100 index (+0.91%).

There was one major changeΒ to the list this week.

Datadog (+3.04%) replaced Marvell Technology (+0.81%) on the list.


The Growth-Centric Russell 2000

The Russell 2000 Top 25 list (+3.79%) outperformed the Russell 2000 index (+0.54%).

There wereΒ two major changesΒ to the list this week.

Joining:Β Aveanna Healthcare (+2.71%) and Dream Finders Homes (+0.45%).

Leaving:Β Innodata Inc (-24.55%) andΒ Reneo Pharmaceuticals (-7.99%).



The Top 25 lists’ Top Dawg was Inozyne Pharma, which rallied 20.55%. πŸ“ˆ

The micro-cap clinical-stage biopharmaceutical company didn’t have any specific news related to it this week. It just seems to be rebounding with the broader biotechnology industry, which has had a rough 2023 so far. 🀷

Notably, the Stocktwits community has maintained a neutral to bearish sentiment rating despite the stock’s recent rebound. 🐻

$INZY is up 274.29% YTD.

See Y’all Next Week πŸ€™